Starpharmaの利益マージン
Starpharmaの利益マージンは何ですか。
Starpharma Holdings Limitedの利益マージンは-83.61%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
ASXのセクタHealth Careにおける利益マージンの企業と比べるStarpharma
Starpharmaは何をしますか。
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharmaと類似の利益マージン
- Digihost Technologyの利益マージンは-83.84%です。
- Rokk3rの利益マージンは-83.83%です。
- Genfit SAの利益マージンは-83.79%です。
- Genfit SAの利益マージンは-83.79%です。
- PetroNeft Resources plcの利益マージンは-83.70%です。
- PetroNeft Resources plcの利益マージンは-83.68%です。
- Starpharmaの利益マージンは-83.61%です。
- Twist Bioscience Corpの利益マージンは-83.48%です。
- Rentian Technologyの利益マージンは-83.46%です。
- Time Out plcの利益マージンは-83.35%です。
- Tinybeansの利益マージンは-83.18%です。
- Ekso Bionics Incの利益マージンは-83.14%です。
- Wunong Net Technologyの利益マージンは-82.94%です。